Progyny (NASDAQ:PGNY) Now Covered by Wells Fargo & Company

Equities research analysts at Wells Fargo & Company assumed coverage on shares of Progyny (NASDAQ:PGNY) in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm set an “overweight” rating and a $37.00 price target on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 48.70% from the company’s previous close.

Several other brokerages have also recently issued reports on PGNY. Wall Street Zen raised Progyny from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 19th. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Weiss Ratings lowered shares of Progyny from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, August 31st. Citizens Jmp boosted their target price on Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a report on Tuesday, September 8th. Finally, Bank of America raised their price objective on Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $34.36.

Progyny Trading Up 0.4%

PGNY opened at $24.88 on Wednesday. The stock’s 50-day moving average price is $27.49 and its 200 day moving average price is $24.69. Progyny has a 12-month low of $16.10 and a 12-month high of $33.06. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of 27.15, a PEG ratio of 1.76 and a beta of 0.99.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The business had revenue of $350.51 million during the quarter, compared to the consensus estimate of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, research analysts forecast that Progyny will post 1.25 earnings per share for the current year.

Insider Buying and Selling at Progyny

In other Progyny news, Director Kevin Gordon sold 11,500 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $27.94, for a total value of $321,310.00. Following the completion of the transaction, the director directly owned 6,792 shares in the company, valued at approximately $189,768.48. This trade represents a 62.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Allison Swartz sold 3,903 shares of Progyny stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total value of $101,868.30. Following the sale, the executive vice president directly owned 75,816 shares in the company, valued at $1,978,797.60. The trade was a 4.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Progyny

A number of institutional investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio bought a new position in Progyny in the 2nd quarter worth about $29,000. Nykredit A S bought a new position in shares of Progyny in the second quarter worth approximately $38,000. Hantz Financial Services Inc. boosted its position in shares of Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after purchasing an additional 742 shares during the period. IFP Advisors Inc increased its stake in shares of Progyny by 376.0% in the second quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after purchasing an additional 1,549 shares in the last quarter. Finally, Toth Financial Advisory Corp purchased a new stake in shares of Progyny in the second quarter worth $65,000. 94.93% of the stock is owned by institutional investors.

About Progyny

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company’s services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.